Clinical trials
Breast Cancer Female clinical trials
Below are recruiting breast cancer female clinical trials, each written for real people, not researchers. We’re tracking 1,100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT06313086RecruitingPhase 3
New drug vs. T-DM1 for HER2-positive advanced breast cancer
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07810088RecruitingPhase 2
Dalpiciclib with hormone therapy and blood pressure drug for advanced breast cancer
This trial is testing a new combination of medicines — a CDK4/6 inhibitor (dalpiciclib) plus hormone therapy and a blood pressure drug (olmesartan) — as a first treatment for advanced hormone-positive breast cancer. The goal is to see if this combination helps slow or shrink the cancer better than standard care.
Wuhan, HubeiAges 18–75 - NCT07731477Recruiting
Virtual reality mindfulness for anxiety in breast cancer chemo
This study tests if using virtual reality for mindfulness exercises can help reduce anxiety, improve comfort, sleep, and fatigue in women with breast cancer who are about to start chemotherapy. It compares VR mindfulness to standard care.
Ankara, AnkaraAges 18 years+ - NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75 - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07616427RecruitingPhase 2
New drug plus hormone therapy for HER2-positive breast cancer
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07616440Recruiting
Ultrasound drug delivery with chemotherapy for HER2-positive breast cancer
This study tests a new technique that uses focused ultrasound to deliver cancer drugs directly to breast tumors, combined with standard chemotherapy. The goal is to improve treatment effectiveness for HER2-positive breast cancer before surgery.
Hangzhou, ZhejiangAges 18–70 - NCT06340230RecruitingPhase 2
New drug combination before surgery for HR+ HER2-low breast cancer
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
Shenyang, LiaoningAges 18–75 - NCT06717984Recruiting
AI model for breast cancer from tissue images
This trial tests an artificial intelligence (AI) model that looks at pictures of breast tissue to find cancer. It may help improve early detection and reduce the need for invasive tests.
DhakaAges Any age - NCT07531693Recruiting
Improving Outcomes in Early Hormone-Positive Breast Cancer
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
Erlangen, BavariaAges 18 years+ - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT06492005RecruitingPhase 2
Study of 9MW2821 for advanced triple-negative breast cancer
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07457359RecruitingPhase 2
Toripalimab plus radiation for chemo-resistant triple-negative breast cancer
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
HangzhouAges 18–75 - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07319195RecruitingEarly Phase 1
Study of a new drug injected into tumors for breast cancer
This trial tests a drug called mitazalimab injected directly into the tumor for patients with early-stage or recurrent breast cancer who are scheduled for surgery. The goal is to see if this approach can help the immune system fight the cancer before surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07299825RecruitingPhase 2
Study of A166 for advanced HER2-positive breast cancer
This trial tests a new drug called A166 for people with HER2-positive breast cancer that has spread or can't be removed. It is for those who have already tried up to five treatments, including a specific type of HER2 antibody-drug conjugate.
Zhenzhou, HenanAges 18–75 - NCT03671044RecruitingPhase 3
Testing a nano-form of docetaxel for triple-negative breast cancer
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
Columbus, GeorgiaAges 18–65 - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07257484RecruitingPhase 4
Tirzepatide study for breast cancer survivors with obesity
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
New York, New YorkAges 18 years+ - NCT07236658Recruiting
Using AI to detect arm problems after breast cancer surgery
This trial uses artificial intelligence (a computer program) to help predict arm and shoulder problems that can happen after breast cancer surgery. It aims to find these issues early so they can be treated better.
AnkaraAges 18 years+
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer female?
- Yes. Clin2 currently lists 1,100 recruiting breast cancer female studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer female trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer female trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.